Disease
|
Drug/Important Bio-Agent (IBA)
| 1 | Apolipoproteins B (ApoB)IBA
11/2023 |
| 1 | Apolipoprotein A-I (Apolipoprotein A1)IBA
11/2023 |
| 1 | Peptides (Polypeptides)IBA
08/2023 |
| 1 | aspartylglutamateIBA
08/2023 |
| 1 | alanylaspartic acidIBA
08/2023 |
| 1 | Histamine Antagonists (Antihistamines)IBA
07/2023 |
| 1 | SteroidsIBA
07/2023 |
| 1 | EnzymesIBA
01/2023 |
| 1 | Amyloid (Amyloid Fibrils)IBA
01/2023 |
| 1 | Receptor Tyrosine Kinase-like Orphan ReceptorsIBA
12/2022 |
| 1 | Membrane Proteins (Integral Membrane Proteins)IBA
12/2022 |
| 1 | Proteins (Proteins, Gene)FDA Link
12/2022 |
| 1 | asphaltIBA
08/2022 |
| 1 | Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2022 |
| 1 | Antimicrobial PeptidesIBA
08/2021 |
| 1 | perfluoro- 2,2,2',2'- tetramethyl- 4,4'- bis(1,3- dioxolane)IBA
05/2015 |
| 1 | ManganeseIBA
01/2011 |
| 1 | Local AnestheticsIBA
11/2010 |
| 1 | gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetateIBA
11/2008 |
| 1 | Contrast MediaIBA
11/2008 |
| 1 | 5- (benzoylamino)- N- (4- chlorophenyl)- 3- methyl- 4- isothiazolecarboxamide (ITCL)IBA
11/2008 |
|
Therapy/Procedure
|